A randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI
Background Ischemia-reperfusion injury remains a major clinical problem in patients with ST-elevation myocardial infarction (STEMI), leading to myocardial damage despite early reperfusion by primary percutaneous coronary intervention (PPCI). There are no effective therapies to limit ischemia-reperfu...
Үндсэн зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
Elsevier
2021
|